Home › NCT06972719

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

Recruiting

Patient Centered Education About Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy: a Pilot Randomized Controlled Trial

Who can join

Ages 19 to 50 · Women

Full eligibility criteria

Inclusion Criteria:

* BRCA1 or BRCA2 germline mutation
* scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist
* premenopausal

Exclusion Criteria:

* personal history of cancer
* postmenopausal
* \>50 years old
* unable to provide informed consent in English

About the study

The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).

What is being tested

Experimental Arm (behavioral)
SOC Arm (behavioral)

Sponsor: Duke University · Participants: 50 · Started: Sep 30, 2025

Contact the study team

Amelia Scott · Phone: (919) 613-4584

Official record on ClinicalTrials.gov — NCT06972719

Locations in the U.S.

North Carolina

UNC Chapel Hill Health System, Chapel Hill
Duke University Health System, Durham

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.